Mechanisms of camptothecin resistance by human topoisomerase I mutations.
about
Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505Targeting DNA topoisomerase II in cancer chemotherapyMolecular basis of antibiotic multiresistance transfer in Staphylococcus aureusExploring DNA topoisomerase I ligand space in search of novel anticancer agentsThe structure–activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding modeSynthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: Investigating the hypothesis of shared structure–activity relationshipsAdvantages of an optical nanosensor system for the mechanistic analysis of a novel topoisomerase I targeting drug: a case study.Arylstibonic acids: novel inhibitors and activators of human topoisomerase IBDesign, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.Free energy calculations reveal rotating-ratchet mechanism for DNA supercoil relaxation by topoisomerase IB and its inhibition.Characterization of DNA topoisomerase-1 in Spodoptera exigua for toxicity evaluation of camptothecin and hydoxy-camptothecin.The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.Quantitative interactome analysis reveals a chemoresistant edgotype.Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descentIdentification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase IRepair of topoisomerase I-mediated DNA damage.Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plantsSingle-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence.Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutationsThr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations.Structural studies of type I topoisomerases.Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.DNA topoisomerases: harnessing and constraining energy to govern chromosome topology.Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalphaEvidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).Interfacial inhibitors: targeting macromolecular complexes.Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?New Topoisomerase I mutations are associated with resistance to camptothecinRad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.Role of the protein in the DNA sequence specificity of the cleavage site stabilized by the camptothecin topoisomerase IB inhibitor: a metadynamics study.Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.Chromatin determinants impart camptothecin sensitivity.Crystal structure of a bacterial type IB DNA topoisomerase reveals a preassembled active site in the absence of DNA.
P2860
Q24299998-539CD844-0D58-4F91-BF22-B5BC62C8BF4FQ24649711-B2E50CC0-43E6-4F07-8B2B-1BB829491C45Q27676045-B249EAB1-77CF-4686-BAB4-F8C77E57FBA0Q28477194-64A71123-6A5A-48DF-90C6-83479B2E6239Q29028715-73E74EC4-1C2F-4A8D-907D-F378B3ED4FBEQ29038255-0E842B00-5322-4DB1-AC0F-DF0B1C448BB4Q31155008-DC927D55-034A-454F-A458-BC394B8E6E59Q33338330-3A6C2673-2FC3-466A-BFA1-E7A978AB83EAQ33662415-01C71822-23B3-4E68-868E-F8B7DAFBF488Q33812633-95609DF3-AB07-4108-8EF2-E4182FBAEF24Q33925798-02B52774-C068-4951-AB8D-A6834BC8E924Q34032792-DC7C5CAD-B566-4E79-9366-20DD9973D8E9Q34602383-3F161EE3-7A27-4D52-91C0-85D97B4582BDQ35130480-6E5101B0-0DFE-4729-86ED-B094B794CB87Q35583096-0C29EA60-4625-4293-AC19-08BBD9D808E5Q35941833-A2BA1940-EF5B-4872-9BC7-BDAE80D64B3FQ36126605-9B9D55AD-DC39-4447-A8CF-7552BB7890E4Q36525254-FC6C5275-278D-447C-9160-E8272D0C57E0Q36557533-F6100B3D-6756-4462-A3CA-8A08FAC2DCE8Q36627605-41201DD1-B3B4-4C0B-907B-18679222D736Q36633210-18BAE903-190D-4629-9057-90AA7170A385Q36749303-EAB5433E-0FE6-456B-9495-DF40A10FBDB1Q36909287-3D414390-BAA0-4828-B772-B9B21D73C4A9Q37108394-551BAF97-B56C-41E3-8E8B-D8F5A2998ECCQ37197502-975D27C9-FE1F-4064-A9EF-2B722DBB021AQ37199784-E4B42CB5-2D2A-4494-898E-F942223511DAQ37255381-3FF9EB26-A0DA-457C-95B1-04EA86C0D73AQ37323539-A560A5CA-4F31-49EF-B0B3-2B87BA8D1327Q37421089-41739A95-ECA6-4C3B-A9FD-78243B04F6FCQ37652515-913A3444-FF62-46E9-A1DA-501861DE233FQ37968897-4FC10CB4-3FFD-419E-919F-CBFE60439606Q38968355-BDC6DEDA-0832-4671-9D80-772C597361F9Q39534943-3713C74F-34D4-4CE0-BD31-624A91987EBEQ39561547-274A9AA7-829F-4497-9048-CD805392EC3DQ40308617-6D659C87-75A5-4DB1-8AFD-6610F69CFC89Q41898399-1EE3C176-69CD-4E65-A3E8-6B007247C3E5Q41912277-1BDE78E1-228A-4833-AAC8-1E2C87FA726AQ41985872-A9935876-2841-461A-9188-3BDCA3E37033Q42233645-C41EDCDF-AA3D-448B-8D9E-18E7ADD5EB05Q42676269-EFF830F7-06BC-4AC3-81C7-CEF4D9149624
P2860
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
@en
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
@nl
type
label
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
@en
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
@nl
prefLabel
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
@en
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
@nl
P2093
P1476
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
@en
P2093
Alex B Burgin
Bart L Staker
Jill E Chrencik
Lance Stewart
Philippe Pourquier
P304
P356
10.1016/J.JMB.2004.03.077
P407
P577
2004-06-01T00:00:00Z